Back to Search
Start Over
AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization
- Source :
- International journal of cardiology. 101(2)
- Publication Year :
- 2003
-
Abstract
- Background: C34T variant of adenosine monophosphate deaminase 1 (AMPD1) gene has been associated with a prolonged survival in heart failure and coronary artery disease, hypothetically linked to an enhanced production of adenosine. Design: Since adenosine administration is a promising approach for the prevention of the ischemia–reperfusion in myocardial revascularization, the aim of this study was to investigate whether the AMPD1 (−) allele is associated with a favorable prognosis after coronary revascularization. In addition, we assessed the association between AMPD1 polymorphism and plasma adenosine levels. Methods: We investigated a total of 161 patients receiving coronary revascularization (70 percutaneous transluminal coronary angioplasty and 91 coronary artery bypass graft). They were investigated for a composite endpoint including recurrent angina, non-fatal MI, target vessel revascularization, heart failure and cardiac death. Plasma adenosine was also measured by high-performance liquid chromatography methods on a subset of 25 patients. Results: During the follow-up period (7.0±0.3 months), the overall combined endpoint accounted for 17 events (10 cardiac-related deaths, 6 revascularization procedures and 1 congestive heart failure). The composite endpoint was 9.8% for AMPD1 (−) allele carriers vs. 11.5% for non-carriers (log-rank statistic, p =n.s.). In the logistic analysis only low (≤40%) ejection fraction was an independent predictor of adverse events ( p =0.01, OR=3.8, 95% CI 1.3–11.4). Plasma adenosine levels were similar for AMPD1 (−) allele patients ( n =7) as compared for AMPD1 (+) allele ( n =18) subjects (290.5±31.0 vs. 303.3±28.5 nM, p =n.s.). Conclusions: Our results indicate that AMPD1 (−) allele is not associated with a more favorable outcome after coronary revascularization. Alternative cardioprotective pathways of the AMPD1 gene—involving an enhanced chronic long-term production of adenosine—might be responsible for survival.
- Subjects :
- Male
medicine.medical_specialty
Adenosine
Genotype
medicine.medical_treatment
Coronary Artery Disease
Revascularization
AMP Deaminase
Coronary artery disease
Angina
Internal medicine
medicine
Humans
Angioplasty, Balloon, Coronary
Coronary Artery Bypass
Aged
Ejection fraction
Polymorphism, Genetic
business.industry
Middle Aged
medicine.disease
medicine.anatomical_structure
Treatment Outcome
Heart failure
Circulatory system
Cardiology
Female
Cardiology and Cardiovascular Medicine
business
medicine.drug
Artery
Follow-Up Studies
Subjects
Details
- ISSN :
- 01675273
- Volume :
- 101
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- International journal of cardiology
- Accession number :
- edsair.doi.dedup.....0dbaab9ebb1f82d5dc0562bf7411de46